Lantheus Secures FDA Tentative Approval for Lutathera® Radioequivalent
LNTH sits 59% above its 52-week low of $47.25.
Summary
Lantheus Holdings has received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), a radiopharmaceutical equivalent to Lutathera®. This significant regulatory milestone aligns with the company's recently announced strategic pivot towards radiodiagnostics and radiotherapeutics, as detailed in its Q4/FY25 earnings and 10-K filing on February 26. The tentative approval for a drug equivalent to an established product like Lutathera® positions Lantheus to potentially capture market share in the neuroendocrine tumor treatment space, representing a material future revenue opportunity. Traders will be watching for final approval and commercialization plans, as this development strengthens the company's product pipeline and strategic direction.
At the time of this announcement, LNTH was trading at $75.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $47.25 to $111.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.